Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0000905148-26-002500

Chief Development Officer gave up 404 shares (to pay taxes)

From the SEC's structured data for this filing

Trades in this filing

Gamelin Erick · Chief Development Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2026-05-14 Shares withheld for taxes : show line 1 in the form −404 $1.92 $776 14,408 D
Loading xslF345X06/form4.xml…